HISHOH Biopharma㈱
2 known investors
HISHOH Biopharma develops novel immunotherapy drugs based on allergen immunotherapy (including sublingual immunotherapy) to treat IgE-mediated Type I allergic diseases such as allergic rhinitis, asthma, and atopic dermatitis. Its lead candidate, HSO-001, aims to lower antibody levels associated with pollen allergy for faster and longer-lasting effects.
Founders & leadership
NS
Naoki SakuraiRepresentative Director & President
TS
Toru SeoDirector / Chief Business Development Officer
JH
Joji HayashidaDirector / Chief Operating Officer
Investors · 2
Frequently asked questions
- What does HISHOH Biopharma㈱ do?
- HISHOH Biopharma develops novel immunotherapy drugs based on allergen immunotherapy (including sublingual immunotherapy) to treat IgE-mediated Type I allergic diseases such as allergic rhinitis, asthma, and atopic dermatitis. Its lead candidate, HSO-001, aims to lower antibody levels associated with pollen allergy for faster and longer-lasting effects.
- Who are HISHOH Biopharma㈱'s investors?
- HISHOH Biopharma㈱'s investors include DBJ Capital, Mitsubishi UFJ Capital.